Founder & President
30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®, Vioxx®, Arcoxia®, Previcox®, Tredaptive® and Odanacatib. Recipient of Heroes of Chemistry award and two time recipient of Prix Galien.
Founder and former CEO of Datapoint Diagnostics, and co-founder of C7bio. Prior he ran business development for Intelescope, an Israeli agritech company. Jon started out in capital markets at Perimeter (portfolio of Goldman Sachs) where he created the first depth-of-book distressed debt electronic trading platform.
Chief Medical Officer
Dr. Mehta is a board certified endocrinologist currently practicing at Stanford Medical Partners. He has served as Principal Investigator on numerous clinical trials across a range of metabolic conditions. Previously with the healthcare investment banking group at Lazard.
Chief Development Officer
Dr. Tam has 20 years of industrial experience in nonclinical and clinical drug development. Pat trained as a toxicologist and has expertise across early-phase drug development, pharmacology, bioanalytical method development and Phase I-II clinical program development and operations.
Linda's background is in accounting. She supports Mesentech in establishing new internal processes, supporting ongoing operations and financial tracking.
Gang Chen, PhD
Dr. Chen has over 20 years of experience in the biotech industry and played instrumental roles in two public companies (AnorMED and Cardiome). He has extensive experience in medicinal chemistry, process development, and analytical chemistry. He is the joint inventor of nine patents and co-author of 30 peer-reviewed journal articles.
Medicinal Chemist with four years for Postdoctoral research experience on the development of bone targetting conjugates. Previously worked on development of drug-like small molecules as amyloid-beta fibrillation inhibitors for Alzheimer's Disease.
David Hyman is a Chartered Accountant and Chartered Business Valuator with over 20 years of experience in financial and economic analysis for public and private enterprises in addition to financial governance and public accounting. Mr. Hyman is currently a contract CFO with Tandem Innovation Group where he provides fractional CFO services to small and medium size businesses. Prior thereto, Mr. Hyman previously served as CFO of TheraCann International, a cannabis technology and consulting company with international operations. Prior to TheraCann, David was CFO of Merrco Payments Inc., a private payment processing company and prior thereto was Vice President at Camcor Partners Ltd., an energy focused private equity firm. Mr. Hyman holds a B.Comm. from the University of Calgary.
Jay Mohr BA, MBA
Partner emeritus of Locust Walk Partners, Founding CEO and Director for Gloucester Pharmaceuticals (acquired by Celgene for $640M). Currently serves as Director of the T1D Exchange, a nonprofit organization accelerating therapies for type 1 diabetes.
Dr. Samuel Wu MD, PhD
Previously managing director of MedImmune (AstraZeneca) Ventures, principal at SV Life Sciences. Prior to his VC career, Sam was an Engagement Manager with McKinsey and Company. Sam obtained an M.D. Ph.D. from Stanford University School of Medicine and an S.B. magna cum laude from Harvard University.
Barbara Yanni currently serves as an independent director of two public clinical-stage biopharmaceutical companies: Trevena (TRVN) and Vaccinex (VCNX). She is also a member of the Board of Supervisory Directors of Pharming Group NV and former director of Akcea (AKCA), Abionyx (ABNX) and Symic Bio.
Serial CEO with 8 positive exits for shareholders. Current CEO of Likeminds, former CEO of Alseres, Aderis developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease. Former leadership roles at Unisyn, Bristol Meyers, Waters, Millipore, Genex and Zymark.
David C. Dvorak
David served as President and Chief Executive Officer of Zimmer Biomet (NYSE and SIX: ZBH) from 2007 to 2017. During his 16-year tenure with Zimmer Biomet revenues and capitalization grew by 500% to $7.7 billion, and 300% to $26 billion respectively.
Bob oversaw Radius Health’s IPO (2014) and FDA approval of TYMLOS®. Subsequently Bob served as Chairman Chief Executive Officer for Eloxx Pharmaceuticals uplisting the Company to NASDAQ. Bob was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca.
Dr. Michael Kelly
Kelly brings 25 years experience in drug discovery and development previously serving as president and U.S. site head of Renovis and senior positions at Amgen, Wyeth (Pfizer) and Wellcome (GSK).
Roland Baron DDS PhD
Prior to joining at MGH, Baron was professor of orthopedics and cell biology at Yale University School of Medicine and editor-in-chief of the Journal of the International Bone and Mineral Society. Formerly head of bone diseases at Hoechst Marion Roussel (Aventis).
Director of Metabolic Bone Diseases and Osteoporosis; formerly Chief of the Bone Tumor Service (osteogenic sarcoma, Ewing’s sarcoma) at Memorial Sloan Kettering Cancer Center.
Navdeep Tangri MD
Nephrologist, Professor of Medicine at University of Manitoba. Advised Tricida on developing metabolic acidosis as a surrogate end point, resulting in NDA for accelerated approval in renal disease. Developed the Kidney Failure Risk Equation to predict need for dialysis in patients with CKD. Conducted large prospective study on frailty, physical and cognitive function in advanced CKD. Recipient of the CIHR New Investigator Award, and a CIHR Foundation grant
Leading foundational research on mechanisms regulating the development, maintenance and regeneration of the skeleton. Professor in the Dept. of Cellular and Physiological Sciences and the Biomedical Research Centre, UBC.
Peter K. S. Siegl, Ph.D.
Practical experience advancing candidates into clinical development gained over 27 year tenure at Merck Research Labs, holding global responsibilities in discovery, development and portfolio management.